[1] 崔艳丽,赵秀丽,武 峰,等.胆固醇酯转运蛋白基因TaqⅠ多态性与多廿烷醇降脂疗效的关系[J].中国新药杂志,2007,16(3):240-243.
[2] Menendez R,Marrero D,Mas R,et al.In vitro and in vivo study of octacosanol metabolism[J].Arch Med Res,2005,36(2):113-119.
[3] Menéndez R,Fraga V,Amor AM,et al.Oral administration of policosanol inhibits in vitro copper ion-induced rat lipoprotein peroxidation[J].Physiol Behav,1999,67(1):1-7.
[4] 多廿烷醇临床应用专家共识组.新型调脂植物药——多廿烷醇临床应用专家共识[J].中华内科杂志,2008,11(47):961-963.
[5] Menendez R,Amor AM,Rodeiro I,et al.Policosanol modulates HMG-CoA reductase activity in cultured fibroblasts[J].Arch Med Res,2001,32(1):8-12.
[6] Singh DK,Li L,Porter TD.Policosanol inhibits cholesterol synthesis in hepatoma cells by activation of AMP-kinase[J].J Pharmacol Exp Ther, 2006,318(3):1020-1026.
[7] 中华心血管杂志编委会心血管药物对策专题组.心血管药物临床试验评价方法的建议[J].中华心血管病杂志,1998,26(1):5-11.
[8] 申 琳,崔 君.多廿烷醇和瑞舒伐他汀治疗老年高脂血症的成本-效果分析[J].临床误诊误治,2011,24(10):87-89.
[9] 丁 宇,司全金.多廿烷醇在老年心血管病患者调脂治疗中的有效性及安全性分析[J].中华老年心脑血管病杂志,2015,17(6):575-579.
[10] Castaño G,Fernández L, Mas R,et al.Comparison ofthe effects of policosanol and atorva-statinon lipid profile and platelet aggregation in patients with dyslipidaemia and type 2 diabetes mellitus[J].Clin Drug Investig,2003,23(10):639-650.
[11] Castaño G,Mas R,Fernández L,et al.Comparison of the efficacy and tolerability of policosanol withatorvastatin in elderly patients with type Ⅱ hypercholesterolaemia[J].Drugs Aging,2003,20(2):153-163.
[12] Castaño G,Illnait J,Fernández L,et al.Comparison of the effects of policosanol and atorvastatin on postmenopausal women with type Ⅱ hypercholesterolemia[J].Revista Cenic Ciencias Biológicas, 2008,39(1):27-32.
[13] 孙 静,武 强,龙 梅.多廿烷醇与阿托伐他汀治疗高脂血症的疗效对比[J].军医进修学院学报,2011,32(10):1023-1024,1029.
[14] 郑明华,施可庆,张天嵩,等.Meta分析软件应用与实例解析[M].北京:人民卫生出版社,2013:78.
[15] 李 莹,陈志红,周北凡,等.血脂和脂蛋白水平对我国中年人群缺血性心血管病事件的预测作用[J].中华心血管病杂志.2004,32(7):643-647.
[16] 蔡德山.浅析天然调血脂药物"多廿烷醇" [J].中国制药信息,2014,30(10):10-14.
[17] 徐同成,李 霞,王文亮,等.分类变量Meta分析中偏倚的检测-Egger法和Begg法[J].循证医学,2009,3:181-184.
[18] 魏丽娟,董惠娟.Meta分析中异质性的识别与处理[J].第二军医大学学报,2006,27(4):449-450.